P4, N=350, Not yet recruiting, Zhongshan Hospital Affiliated to Fudan University; Zhongshan Hospital Affiliated to Fudan University

P2, N=27, Not yet recruiting, The Second Affiliated hospital of Fujian Medical University; The Second Affiliated hospital of Fujian Medical University

P2, N=20, Completed, Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University

P2, N=30, Completed, Department of Radiation Oncology, the First Medical Center, Chinese People's Liberation Army (PLA) General Hospital; The First Medical Center, Chinese

The effect of RT (8 and 3 × 8 Gy) on Interferon beta (IFNβ), IFN-stimulated genes (ISGs), and HLA-class-I expression in combination with IFN-type-I-response inhibitors (Ruxolitinib, Tofacitinib, Amlexanox) targeting the JAK and TBK1 was studied with Flow cytometry and RT-PCR. The current study supports the theory that baseline autophagy, RT-induced autophagy blockage, and IFN-type-I response enhancement define the HLA-class-I levels in NSCLC cells. This complex interplay emerges as a promising target for the development of radio-vaccination strategies to enhance the efficacy of radio-immunotherapy.

P2, N=96, Recruiting, Shanghai Chest Hospital

P1/2, N=58, Recruiting, Kidney Cancer Research Bureau | Active, not recruiting --> Recruiting

In the first-line setting, targeted therapy and SSAs were associated with longer PFS than chemotherapy, with surufatinib and lanreotide showing favorable disease control. SDHx pathogenic variant status did not show a clear association with response to TKIs or temozolomide, underscoring the need for validation in larger cohorts.

P2/3, N=235, Recruiting, Hutchmed | Phase classification: P2 --> P2/3 | N=128 --> 235 | Trial completion date: Dec 2025 --> Feb 2030 | Trial primary completion date: Jun 2025 --> Jun 2028

P2/3, N=502, Recruiting, Hutchmed | Trial completion date: Aug 2027 --> May 2028 | Trial primary completion date: Aug 2027 --> May 2028

FGFR1 plays a role in the resistance to immune checkpoint inhibitors (ICIs) such as pembrolizumab and nivolumab...Based on the FGFR1-related research and the active targeting strategy, we believe that modifying the surface of nanomedicines with anti-FGFR1 antibodies (such as OM-RCA-01) is an effective targeted treatment method for tumors with high expression of FGFR1. Although there have been relevant studies confirming the feasibility of this approach, there are challenges in clinical application, especially in terms of maintaining uniform quality during large-scale production. Therefore, we suggest conducting further optimization studies in the future to accelerate the clinical application of such drug delivery systems and provide more efficient and cost-effective options for tumor treatment.

P4, N=350, Recruiting, Shanghai Zhongshan Hospital | Not yet recruiting --> Recruiting